These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 18946341)

  • 1. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.
    van Gelder T; Silva HT; de Fijter JW; Budde K; Kuypers D; Tyden G; Lohmus A; Sommerer C; Hartmann A; Le Meur Y; Oellerich M; Holt DW; Tönshoff B; Keown P; Campbell S; Mamelok RD
    Transplantation; 2008 Oct; 86(8):1043-51. PubMed ID: 18946341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
    Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
    Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients.
    Prémaud A; Rousseau A; Le Meur Y; Venisse N; Loichot C; Turcant A; Hoizey G; Compagnon P; Hary L; Debruyne D; Saivin S; Jacqz-Aigrain E; Marquet P
    Pharmacol Res; 2010 Feb; 61(2):167-74. PubMed ID: 19800973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term therapeutic drug monitoring of mycophenolic acid reduces infection: a prospective, single-center cohort study in Chinese living-related kidney transplantation.
    Fu L; Huang Z; Song T; He S; Zeng D; Rao Z; Xie L; Song Y; Wang L; Lin T
    Transpl Infect Dis; 2014 Oct; 16(5):760-6. PubMed ID: 25092411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.
    Gourishankar S; Houde I; Keown PA; Landsberg D; Cardella CJ; Barama AA; Dandavino R; Shoker A; Pirc L; Wrobel MM; Kiberd BA
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1282-9. PubMed ID: 20498245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil.
    Le Meur Y; Thierry A; Glowacki F; Rerolle JP; Garrigue V; Ouali N; Heng AE; Delahousse M; Albano L; Lang P; Couzi L; Jaureguy M; Lebranchu Y; Mousson C; Glotz D; Kessler M; Vrtovsnik F; Rouanet S; Tagieva N; Kamar N
    Transplantation; 2011 Dec; 92(11):1244-51. PubMed ID: 22067312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
    Kiberd BA; Lawen J; Daley C
    Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
    van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
    Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
    Cooper M; Deering KL; Slakey DP; Harshaw Q; Arcona S; McCann EL; Rasetto FA; Florman SS
    Transplantation; 2009 Aug; 88(4):514-20. PubMed ID: 19696634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses.
    Kamar N; Marquet P; Gandia P; Muscari F; Lavayssière L; Esposito L; Guitard J; Canivet C; Peron JM; Alric L; Suc B; Saint-Marcoux F; Rostaing L
    Ther Drug Monit; 2009 Aug; 31(4):451-6. PubMed ID: 19531983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of dose reductions on efficacy outcome in heart transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil at 12 months post-transplantation.
    Segovia J; Gerosa G; Almenar L; Livi U; Viganò M; Arizón JM; Yonan N; Di Salvo TG; Renlund DG; Kobashigawa JA;
    Clin Transplant; 2008; 22(6):809-14. PubMed ID: 18702660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
    van Gelder T; Silva HT; de Fijter H; Budde K; Kuypers D; Mamelok RD; Armstrong VW; Oellerich M
    Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.
    Gaston RS; Kaplan B; Shah T; Cibrik D; Shaw LM; Angelis M; Mulgaonkar S; Meier-Kriesche HU; Patel D; Bloom RD
    Am J Transplant; 2009 Jul; 9(7):1607-19. PubMed ID: 19459794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
    Barau C; Barrail-Tran A; Hemerziu B; Habes D; Taburet AM; Debray D; Furlan V
    Liver Transpl; 2011 Oct; 17(10):1152-8. PubMed ID: 21695772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
    Kuypers DR; de Jonge H; Naesens M; de Loor H; Halewijck E; Dekens M; Vanrenterghem Y
    Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
    Pape L; Ehrich JH; Offner G
    Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.